Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Behçet's Disease with Neurologic or Vascular Involvement
NCT02756650Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in Behçet's disease (BD), sponsored by Novartis. Primary endpoints: Number of Participants With Attacks at 30 days, Modified Expanded Disability Status Scale at 30 days and 16 more. Started Jun 2016; status: completed.
02
Drugs
canakinumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT02756650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756650.